Research advances in HIV pre-exposure prophylaxis drug

VernacularTitle:HIV暴露前预防药物的研究进展
Author: Qizi LIU ¹ ; Xue YANG ; Peng XU ; Qianqian QIN ; Houlin TANG
Author Information

1. 中国疾病预防控制中心性病艾滋病预防控制中心流行病学室，北京　102206
Keywords: HIV; Oral; Pre-exposure prophylaxis; Long-acting; Antiretroviral drug
From: Chinese Journal of Epidemiology 2022;43(12):2036-2040
CountryChina
Language:Chinese
Abstract: In 2012, the World Health Organization (WHO) released tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis drug to help people at risk of HIV infection in specific populations, and various clinical trials and real-world data have confirmed the effectiveness of TDF/FTC in preventing HIV infection. In 2019, propofol tenofovir combined with emtricitabine (TAF/FTC) was approved in the United States as the second oral drug for pre-exposure prophylaxis(PrEP). However, for people who cannot take the drug or have poor adherence to the drug, second-generation PrEP, or long-acting antiretrovirals, provide more options. This artical reviewed the research progress of the first generation of oral PrEP and the new PrEP developed in recent years to provide reference for the promotion of HIV PrEP in China.